Drug Profile
Abetimus
Alternative Names: Abetimus sodium; LJP 394; RiquentLatest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator La Jolla Pharmaceutical Company
- Class Oligonucleotides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lupus nephritis